Clinical trial
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute…
NCT00016302 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00016302 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
| Official title | The Use of Modified BFM +/- Compound 506U78 (Nelarabine) (NSC# 686673, IND #52611) in an Intensive Chemotherapy Regimen for the Treatment of T-Cell Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Study type | Interventional |
| Conditions | T-cell Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia |
| Intervention type | Drug, Other, Radiation |
| Interventions | prednisone, vincristine sulfate, daunorubicin hydrochloride, asparaginase, methotrexate, cyclophosphamide, cytarabine, mercaptopurine, leucovorin calcium, dexamethasone and 7 more |
| Enrollment | 100 |
| Start date | Apr 1, 2001 |
| Primary completion | Jul 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: